AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
Follow ABBV
Alert me
AbbVie Inc. (ABBV) Free cash flow
AbbVie Inc.'s free cash flow for fiscal 2025 was $17.8B, unchanged from fiscal 2024. Over the twelve months to Sep 30, 2026 it was $18.9B. Over the past ten years it has ranged from $6.6B (fiscal 2016) to $24.2B (fiscal 2022); the current reading is higher than 64% of that period. Free cash flow has fallen for 3 consecutive fiscal years. AbbVie Inc. ranks 4th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $17.8B | (0.09%) |
| FY2024 | $17.8B | (19.17%) |
| FY2023 | $22.1B | (9.02%) |
| FY2022 | $24.2B | 10.27% |
| FY2021 | $22.0B | 30.97% |
| FY2020 | $16.8B | 31.46% |
| FY2019 | $12.8B | (0.13%) |
| FY2018 | $12.8B | 35.61% |
| FY2017 | $9.4B | 43.72% |
| FY2016 | $6.6B | (6.30%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $7.3B | 134.59% |
| Jun 2026 | $3.1B | (12.63%) |
| Mar 2026 | $3.6B | (27.10%) |
| Dec 2025 | $4.9B | (26.40%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| JNJ Johnson & Johnson compare | $21.0B |
| LLY Eli Lilly and Company compare | $19.7B |
| ABBV AbbVie Inc. | $18.9B |
| MRK Merck & Co., Inc. compare | $14.7B |
| NVS Novartis AG compare | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement